
Commentary|Articles|August 8, 2025
Medicaid Cuts Have Far-Reaching Consequences in Women's Health: Alina Salganicoff, PhD
Author(s)Julia Bonavitacola, Alina Salganicoff, PhD
Alina Salganicoff, PhD, discusses the immediate effects of the budget cuts to Medicaid as it pertains to women's health across the country.
Advertisement
Advertisement
The budget bill crafted by Republican lawmakers and dubbed the One Big Beautiful Bill Act contained many changes in funding for health care services, including reductions in funding for Medicaid and the elimination of funding for Planned Parenthood, which could have sizeable effects in rural and women's health. Alina Salganicoff, PhD, senior vice president and director for women's health policy at KFF, spoke with The American Journal of Managed Care® about what these changes in the budget bill can mean for health care across the country.
Related to this article

A JAMA analysis of 2021-2023 death records found heat-related mortality varied sharply by occupation and industry among working-age US adults.

Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.

A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.

A scoping review of 15 studies found psoriasis prevalence markedly lower across 13 indigenous populations worldwide.

An estimated 44,052 sports eye injuries were treated in 2025 and 1262 pickleball eye injuries in 2024; 99% of lawnmower eye injuries were at home.

Teva's Weltruza, a once-monthly subcutaneous olanzapine injection, requires no loading doses, oral supplementation, or postinjection monitoring.

The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Advertisement
Advertisement

